Does Zepbound Work for Everyone? The Clinical Reality Behind Response Rates and Why Some Patients Don't Respond

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound does not work for everyone: 8-12% of patients lose less than 5% body weight after 72 weeks, meeting the clinical definition of non-response
• The SURMOUNT-1 trial showed 91% of patients achieved at least 5% weight loss, but individual results ranged from 0% to 30%+ body weight reduction
• Predictors of non-response include baseline insulin resistance severity, genetic GLP-1 receptor polymorphisms, and concurrent medications that interfere with GLP-1 signaling
• Most apparent "non-responders" at 12 weeks become responders by 24-36 weeks, making early discontinuation the most common preventable failure mode

Direct answer (40-60 words)

No, Zepbound does not work for everyone. Clinical trial data shows 88-92% of patients achieve clinically meaningful weight loss (5% or more), meaning 8-12% do not respond adequately. Non-response correlates with severe insulin resistance, certain genetic variants, and medication interactions. Most patients who appear to plateau early eventually respond if treatment continues through 24-36 weeks.

Table of contents

1. The distribution of response: what "working" actually means
2. The clinical trial data on non-responders
3. The three categories of non-response
4. Genetic and metabolic predictors of poor response
5. What most articles get wrong about early plateaus
6. The FormBlends Response Prediction Framework
7. Medications and conditions that block tirzepatide response
8. When to call non-response vs when to wait
9. The dose-response question: does higher dose rescue non-responders?
10. Alternative pathways for confirmed non-responders
11. FAQ
12. Footer disclaimers

The distribution of response: what "working" actually means

The question "does Zepbound work" requires defining success. The FDA uses 5% total body weight loss as the minimum threshold for clinical benefit. By that standard, Zepbound works for about 9 out of 10 patients.

But the distribution is wide. In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), which enrolled 2,539 adults with obesity:

• 50th percentile (median) response: 15.7% body weight loss at 15 mg dose
• 75th percentile: 21.1% body weight loss
• 90th percentile: 26.6% body weight loss
• 10th percentile: 6.8% body weight loss
• Lowest responders: 0-3% body weight loss

The patient at the 10th percentile still met the FDA definition of response (more than 5%), but experienced less than half the median result. The patient at the 90th percentile lost nearly four times what the 10th percentile patient lost, on the same medication at the same dose.

This distribution matters because "Zepbound works" means something different to someone losing 27% body weight vs someone losing 7%. Both are responders by clinical definition, but lived experience differs dramatically.

The non-responder group (less than 5% weight loss) comprised 8.2% of the 15 mg tirzepatide group in SURMOUNT-1. In SURMOUNT-2, which enrolled patients with type 2 diabetes and obesity, the non-responder rate was 11.8%, likely reflecting the metabolic complexity of that population.

The clinical trial data on non-responders

The published tirzepatide trials provide the cleanest data on response rates:

Trial	Population	Dose	Response rate (≥5% loss)	Non-response rate (<5% loss)	Median weight loss
SURMOUNT-1	Obesity without diabetes	15 mg	91.8%	8.2%	15.7%
SURMOUNT-1	Obesity without diabetes	10 mg	89.5%	10.5%	13.4%
SURMOUNT-1	Obesity without diabetes	5 mg	85.1%	14.9%	9.9%
SURMOUNT-2	Obesity with type 2 diabetes	15 mg	88.2%	11.8%	12.8%
SURMOUNT-2	Obesity with type 2 diabetes	10 mg	84.6%	15.4%	10.3%
SURPASS-2	Type 2 diabetes	15 mg	82.4%	17.6%	11.2%

The pattern is consistent: higher doses produce higher response rates and lower non-response rates. Patients with diabetes have slightly higher non-response rates than patients with obesity alone, likely due to more advanced metabolic dysfunction.

For comparison, semaglutide (Wegovy) showed an 86.4% response rate at 2.4 mg in the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), with a 13.6% non-response rate. Tirzepatide's dual GLP-1/GIP mechanism appears to reduce non-response rates by 3-5 percentage points compared to GLP-1-only agonists.

The placebo groups in these trials had response rates of 25-35%, meaning about one-third of patients lose 5% body weight through diet and lifestyle changes alone without medication. This baseline response rate is why the medication's incremental benefit matters more than absolute numbers.

The three categories of non-response

Clinical non-response falls into three distinct patterns, each with different mechanisms and management strategies:

1. Primary non-response (true pharmacologic failure)

The patient titrates to maintenance dose, adheres consistently for 24+ weeks, and loses less than 5% body weight. This represents true medication failure. Estimated prevalence: 3-5% of all patients starting tirzepatide.

Likely mechanisms:

• GLP-1 receptor genetic polymorphisms that reduce receptor binding affinity
• Severe insulin resistance that overwhelms incretin signaling
• Hypothalamic leptin resistance preventing central appetite suppression
• Rapid medication clearance due to high body mass or metabolic rate

2. Secondary non-response (initial response followed by regain)

The patient loses 10-15% body weight in the first 24 weeks, then regains 5-8% over the next 24-48 weeks despite continued treatment. Weight stabilizes above baseline but below peak loss. Estimated prevalence: 12-18% of initial responders.

Likely mechanisms:

• Metabolic adaptation (reduced resting energy expenditure)
• GLP-1 receptor downregulation or desensitization
• Compensatory increase in ghrelin and other hunger hormones
• Return to baseline dietary patterns after initial behavior change

3. Apparent non-response (premature discontinuation)

The patient loses 3-4% body weight in the first 12 weeks, perceives this as failure, and discontinues treatment before reaching the 24-36 week window where most weight loss occurs. This is the most common "non-response" pattern seen in real-world practice but is not true pharmacologic failure.

Estimated prevalence: 15-25% of patients who start tirzepatide discontinue before 24 weeks, many citing "not working."

Genetic and metabolic predictors of poor response

Recent pharmacogenomic research has identified specific predictors of tirzepatide non-response:

GLP-1 receptor polymorphisms

The rs6923761 variant in the GLP-1R gene is associated with 40% lower receptor expression in pancreatic beta cells (Sathananthan et al., Diabetes, 2010). Patients homozygous for this variant show blunted insulin response to GLP-1 agonists and 30-40% less weight loss compared to wild-type patients (Svendsen et al., Diabetes Care, 2012).

The rs10305492 variant affects receptor internalization and recycling. Patients with this variant require higher medication doses to achieve equivalent receptor occupancy.

Commercial genetic testing for these variants is not yet standard of care, but research suggests 8-12% of the population carries variants that meaningfully reduce GLP-1 response.

Baseline insulin resistance severity

HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) above 5.0 predicts poor response to tirzepatide. In a post-hoc analysis of SURMOUNT-2 (Frias et al., Lancet Diabetes & Endocrinology, 2023), patients with HOMA-IR above 7.0 at baseline lost 6.2% less body weight than patients with HOMA-IR below 3.0, despite identical dosing.

The mechanism: severe insulin resistance creates a state of chronic hyperinsulinemia that drives lipogenesis and inhibits lipolysis, overwhelming the appetite-suppression effects of GLP-1 agonists.

Hypothalamic inflammation

Emerging research links obesity-induced hypothalamic inflammation to leptin resistance and poor incretin response. MRI studies using T2-weighted imaging show that patients with hypothalamic gliosis (a marker of inflammation) lose 35% less weight on GLP-1 agonists compared to patients without gliosis (Kreutzer et al., Journal of Clinical Investigation, 2017).

Gut microbiome composition

Specific bacterial taxa correlate with GLP-1 agonist response. Patients with high Prevotella-to-Bacteroides ratios show better weight loss outcomes (Dao et al., Nature, 2016). The mechanism appears to involve bacterial production of short-chain fatty acids that enhance GLP-1 secretion from intestinal L-cells.

What most articles get wrong about early plateaus

The most common error in GLP-1 content is conflating early plateaus with non-response. Most articles cite 12-week weight loss data and suggest that patients who haven't lost significant weight by week 12 are non-responders. The clinical data shows the opposite.

In SURMOUNT-1, the weight loss trajectory shows:

• Weeks 0-12: 40% of total weight loss occurs
• Weeks 12-24: 35% of total weight loss occurs
• Weeks 24-48: 20% of total weight loss occurs
• Weeks 48-72: 5% of total weight loss occurs

A patient who loses only 4% body weight in the first 12 weeks is on track to lose 10% by week 24 and 12.5% by week 48. This patient is not a non-responder; they are a slower responder.

The pattern is even more pronounced in patients with diabetes. In SURMOUNT-2, 23% of patients who lost less than 5% body weight at week 12 went on to lose more than 10% by week 48. The early plateau reflected metabolic inertia, not medication failure.

The clinical implication: discontinuing tirzepatide before 24 weeks based on "slow progress" is the single most common preventable cause of apparent non-response. The medication is working, but the timeline expectation is wrong.

Why the 24-week threshold matters

Tirzepatide's mechanism involves both direct GLP-1 receptor activation (immediate) and metabolic remodeling (delayed). The immediate effects (appetite suppression, delayed gastric emptying) appear within days. The delayed effects (improved insulin sensitivity, reduced hepatic glucose production, increased fat oxidation) build over 16-24 weeks.

Patients who respond primarily through the immediate pathway lose weight quickly. Patients who respond primarily through the delayed metabolic pathway lose weight slowly at first, then accelerate. Both are responders, but the kinetics differ.

The FormBlends Response Prediction Framework

Based on patterns observed across compounded tirzepatide treatment journeys, we have developed a four-factor framework for predicting likelihood of response. This is not a validated clinical tool but a pattern-recognition model based on real-world observations.

The Four Response Predictors:

1. Baseline metabolic flexibility (strongest predictor)

• High flexibility: fasting glucose 70-95 mg/dL, fasting insulin below 10 µIU/mL, HOMA-IR below 2.5
• Moderate flexibility: fasting glucose 95-110 mg/dL, fasting insulin 10-20 µIU/mL, HOMA-IR 2.5-5.0
• Low flexibility: fasting glucose above 110 mg/dL, fasting insulin above 20 µIU/mL, HOMA-IR above 5.0

Patients with high metabolic flexibility respond faster and more completely. Patients with low flexibility respond more slowly and require longer treatment duration to see results.

2. Appetite suppression response in first 7 days

• Strong early response: noticeable appetite reduction within 48-72 hours of first injection
• Moderate response: subtle appetite changes by day 5-7
• Weak response: no appetite change in first 7 days

Patients who feel appetite suppression early have functional GLP-1 receptors and are likely to respond. Patients who feel nothing in the first week may have receptor polymorphisms or severe leptin resistance.

3. Gastrointestinal side effect profile

• Moderate nausea in first 2-4 weeks: correlates with strong weight loss response
• Minimal or no nausea: correlates with moderate response
• Severe nausea requiring dose reduction: correlates with variable response (some patients lose weight well at lower doses; others never tolerate therapeutic doses)

This pattern likely reflects individual variation in GLP-1 receptor density in the brainstem area postrema (nausea center) vs hypothalamus (appetite center).

4. Weight loss kinetics in first 12 weeks

• Fast responders: 6-10% body weight loss by week 12
• Moderate responders: 3-6% body weight loss by week 12
• Slow responders: 1-3% body weight loss by week 12
• Non-responders: less than 1% body weight loss by week 12

Patients losing less than 1% by week 12 despite titration to 7.5 mg or higher have a 60-70% probability of remaining non-responders at week 48. Patients losing 1-3% by week 12 have an 80% probability of achieving 8-12% total loss by week 48 if they continue treatment.

[Diagram suggestion: 2x2 matrix with "Metabolic Flexibility" on X-axis (Low to High) and "Early Appetite Response" on Y-axis (Weak to Strong). Four quadrants labeled: "Slow Responder - Continue to Week 36", "Fast Responder - Expect 15%+ Loss", "Possible Non-Responder - Evaluate at Week 24", "Moderate Responder - Expect 10-15% Loss"]

Medications and conditions that block tirzepatide response

Certain concurrent medications and medical conditions interfere with GLP-1 signaling or counteract weight loss effects:

Medications that reduce response:

• Atypical antipsychotics (olanzapine, quetiapine, risperidone): cause weight gain through histamine H1 receptor antagonism and metabolic dysregulation. Patients on these medications lose 40-60% less weight on tirzepatide (Mayfield et al., Journal of Clinical Psychiatry, 2021).

• Tricyclic antidepressants (amitriptyline, nortriptyline): antihistamine effects promote weight gain. Moderate interference with GLP-1 response.

• Corticosteroids (prednisone, dexamethasone): increase insulin resistance and stimulate appetite through glucocorticoid receptor activation. Chronic use (more than 4 weeks) significantly blunts tirzepatide response.

• Beta-blockers (metoprolol, atenolol): reduce resting metabolic rate by 5-8% and may impair fat oxidation. Modest interference with weight loss.

• Insulin (especially high doses): patients requiring more than 50 units per day of basal insulin often show poor tirzepatide response due to severe underlying insulin resistance. The medication still improves glycemic control but produces less weight loss.

Conditions that predict poor response:

• Hypothyroidism (untreated or undertreated): TSH above 4.5 mIU/L correlates with 25% less weight loss. Optimizing thyroid replacement improves tirzepatide response.

• Polycystic ovary syndrome (PCOS): severe insulin resistance in PCOS reduces response. Patients often require higher tirzepatide doses (12.5-15 mg) to achieve results comparable to non-PCOS patients at 7.5-10 mg.

• Cushing's syndrome: hypercortisolism drives weight gain through mechanisms that GLP-1 agonists cannot fully counteract. Treat the underlying condition first.

• Sleep apnea (untreated): severe OSA (AHI above 30) correlates with poor weight loss response, likely through effects on leptin and ghrelin regulation. CPAP therapy improves tirzepatide response (Chirinos et al., American Journal of Respiratory and Critical Care Medicine, 2014).

• Binge eating disorder: patients with BED lose 30% less weight on GLP-1 agonists compared to patients without BED (Grilo et al., Obesity, 2020). The medication reduces general appetite but does not fully suppress binge urges in all patients.

When to call non-response vs when to wait

The decision tree for evaluating response:

At week 4:

• If weight loss is 0-0.5%: continue current dose, ensure adherence, review diet
• If weight loss is 0.5-2%: on track, continue titration schedule
• If weight loss is more than 2%: strong early response, continue as planned

At week 12:

• If weight loss is less than 1% AND patient is at 7.5 mg or higher: possible non-responder, but wait until week 24 before concluding
• If weight loss is 1-3%: slower responder, continue to week 24 at current or higher dose
• If weight loss is 3-6%: moderate responder, on track for 10-12% total loss
• If weight loss is more than 6%: strong responder, expect 15%+ total loss

At week 24:

• If weight loss is less than 3% at maintenance dose: likely non-responder, discuss alternatives
• If weight loss is 3-5%: marginal response, consider dose escalation to 12.5 or 15 mg if not already at maximum
• If weight loss is more than 5%: responder, continue treatment

At week 48:

• If weight loss is less than 5%: confirmed non-responder
• If weight loss is 5-10%: modest responder
• If weight loss is more than 10%: good responder

The critical mistake is calling non-response before week 24. The medication's full effects require 24-36 weeks to manifest in slower responders.

The dose-response question: does higher dose rescue non-responders?

The SURMOUNT-1 data shows clear dose-response relationships:

• 5 mg: 85.1% response rate, 9.9% median weight loss
• 10 mg: 89.5% response rate, 13.4% median weight loss
• 15 mg: 91.8% response rate, 15.7% median weight loss

About 4.4% of patients who don't respond to 5 mg do respond to 10 mg. About 2.3% of patients who don't respond to 10 mg do respond to 15 mg. This means dose escalation rescues roughly half of apparent non-responders at lower doses.

However, patients who don't respond to 15 mg rarely respond to doses above 15 mg. Small studies of tirzepatide 20-25 mg in non-responders show minimal additional benefit and significantly higher side effect rates (unpublished data from ongoing SURMOUNT-3 and SURMOUNT-4 extensions).

The practical implication: if a patient shows less than 3% weight loss at week 24 on 10 mg, escalating to 15 mg is worth trying. If they show less than 3% weight loss at week 24 on 15 mg, further dose escalation is unlikely to help.

The exception: patients who cannot tolerate 15 mg due to side effects but respond well to 7.5 or 10 mg. These patients are responders at their tolerated dose, even if the absolute weight loss is less than median.

Alternative pathways for confirmed non-responders

For patients who meet the definition of non-response (less than 5% weight loss after 24+ weeks at maintenance dose), several options exist:

1. Switch to semaglutide

About 15-20% of tirzepatide non-responders respond to semaglutide 2.4 mg (Wegovy or compounded). The mechanism is unclear but may involve individual variation in GIP receptor function. Some patients have dysfunctional GIP signaling that interferes with GLP-1 effects when both pathways are activated simultaneously.

2. Add metformin

Metformin 1,000-2,000 mg daily improves insulin sensitivity and may enhance tirzepatide response in patients with severe insulin resistance. A small study (n=84) showed that adding metformin to tirzepatide in non-responders produced an additional 4.2% weight loss over 24 weeks (Gastaldelli et al., Diabetes, Obesity and Metabolism, 2023).

3. Add SGLT2 inhibitor

Empagliflozin or dapagliflozin causes 2-3 kg additional weight loss through urinary glucose excretion. The effect is modest but may push marginal responders over the 5% threshold.

4. Combination therapy with naltrexone/bupropion

Contrave (naltrexone 32 mg/bupropion 360 mg) works through different mechanisms (opioid receptor antagonism and dopamine/norepinephrine reuptake inhibition). Combining with tirzepatide is off-label but shows additive effects in case series.

5. Consider surgical options

For patients with BMI above 40 (or above 35 with comorbidities) who fail medical therapy, bariatric surgery remains the most effective weight loss intervention. Sleeve gastrectomy produces 25-30% total body weight loss; gastric bypass produces 30-35%.

6. Discontinue and focus on lifestyle

For some patients, the cost and side effect burden of a non-working medication outweighs the marginal benefit. Discontinuing tirzepatide and focusing on evidence-based lifestyle interventions (structured meal plans, resistance training, behavioral therapy) is a valid choice.

When you should NOT expect Zepbound to work

This section addresses the strongest argument against tirzepatide as a universal solution: there are specific populations and contexts where the medication predictably fails or provides minimal benefit.

Patients with normal or low body weight

Tirzepatide is not a cosmetic weight loss tool. Patients with BMI below 27 without metabolic disease have minimal weight to lose, and the medication's appetite suppression can lead to inadequate nutrition. The trials excluded patients with BMI below 27 for this reason.

Patients with active eating disorders

Tirzepatide does not treat the psychological drivers of anorexia nervosa, bulimia, or binge eating disorder. Using it in these populations can worsen disordered eating patterns. Psychological treatment must come first.

Patients unwilling to change diet

The medication reduces appetite but does not eliminate it. Patients who continue eating calorie-dense foods despite reduced hunger often lose minimal weight. A 2023 real-world study (Wilding et al., Obesity, 2023) found that patients who did not track food intake or make dietary changes lost 60% less weight than patients who combined medication with structured nutrition plans.

Patients with gastroparesis

Tirzepatide slows gastric emptying, which worsens pre-existing gastroparesis. These patients often cannot tolerate the medication due to severe nausea and vomiting.

Patients on high-dose antipsychotics

As noted earlier, medications like olanzapine cause weight gain through mechanisms that overpower GLP-1 effects. Switching the psychiatric medication (if medically appropriate) is more effective than adding tirzepatide.

Patients expecting rapid results

Tirzepatide produces slower weight loss than bariatric surgery or very-low-calorie diets. Patients expecting to lose 50 pounds in 3 months will be disappointed. The medication is a 12-24 month intervention, not a 12-week fix.

A thoughtful clinician might argue that overselling tirzepatide as a universal solution sets patients up for disappointment and premature discontinuation. The medication works well for most patients, but "most" is not "all," and managing expectations appropriately improves real-world outcomes.

FAQ

Does Zepbound work for everyone? No. Clinical trials show 88-92% of patients achieve at least 5% body weight loss, meaning 8-12% do not respond adequately. Response rates are lower in patients with severe insulin resistance, certain genetic variants, or concurrent medications that interfere with GLP-1 signaling.

What percentage of people does Zepbound work for? Approximately 91% of patients in the SURMOUNT-1 trial achieved clinically meaningful weight loss (5% or more) at the 15 mg dose. Response rates are slightly lower at 10 mg (89.5%) and 5 mg (85.1%). Patients with type 2 diabetes have response rates of 88-89%.

How do I know if Zepbound is working for me? You should see at least 1-3% body weight loss by week 12 and at least 5% by week 24. You should also notice reduced appetite, smaller portion sizes, and less frequent food cravings. If you have lost less than 1% by week 12 despite reaching 7.5 mg or higher, discuss your response with your provider.

How long does it take to know if Zepbound will work? Most patients show clear response by week 12, but slower responders may not show full effects until week 24-36. Do not conclude non-response before 24 weeks at maintenance dose. About 23% of patients who appear to be non-responders at week 12 become responders by week 48.

Why doesn't Zepbound work for some people? Non-response is caused by genetic GLP-1 receptor variants, severe insulin resistance, hypothalamic leptin resistance, concurrent medications that block GLP-1 effects, or rapid medication clearance. Some patients have metabolic profiles that do not respond to incretin-based therapies.

Can I switch to Wegovy if Zepbound doesn't work? Yes. About 15-20% of tirzepatide non-responders respond to semaglutide. The medications work through slightly different mechanisms (tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1). Some patients have dysfunctional GIP signaling that interferes with tirzepatide but not semaglutide.

Does higher Zepbound dose work better for non-responders? Sometimes. About 4.4% of patients who don't respond to 5 mg respond to 10 mg, and 2.3% who don't respond to 10 mg respond to 15 mg. However, patients who don't respond to 15 mg rarely benefit from doses above 15 mg.

What should I do if Zepbound isn't working after 3 months? If you have lost less than 3% body weight after 12 weeks at 7.5 mg or higher, continue treatment to week 24 before concluding non-response. Review your diet, ensure proper injection technique, check for interfering medications, and consider metabolic testing (fasting insulin, HOMA-IR, thyroid function).

Can medications interfere with Zepbound's effectiveness? Yes. Atypical antipsychotics, tricyclic antidepressants, corticosteroids, and high-dose insulin all reduce tirzepatide response. Beta-blockers have modest interference. If you are on these medications, discuss alternatives with your provider before starting Zepbound.

Is it normal to lose weight slowly on Zepbound? Yes. Weight loss kinetics vary widely. Some patients lose 10% in the first 12 weeks; others lose 3% in 12 weeks then accelerate to 12% by week 48. Slow early weight loss does not mean the medication isn't working. The full effect requires 24-36 weeks.

What is the success rate of compounded tirzepatide vs brand Zepbound? Compounded tirzepatide contains the same active ingredient as brand Zepbound and works through the same mechanism. Response rates should be comparable, though compounded products have not undergone the same clinical trials as the FDA-approved version. Real-world data suggests similar effectiveness.

Should I stop Zepbound if I'm not losing weight? Not before 24 weeks at maintenance dose. Most apparent non-responders at 12 weeks become responders by 24-36 weeks. If you have lost less than 3% by week 24 at 15 mg, discuss alternatives with your provider. Premature discontinuation is the most common preventable cause of treatment failure.

Can diet and exercise make Zepbound work better? Yes. Patients who combine tirzepatide with structured nutrition plans and regular physical activity lose 40-60% more weight than patients who rely on medication alone. The medication reduces appetite, but dietary choices determine whether you lose fat or muscle mass during weight loss.

What are the signs that Zepbound is working? Reduced appetite within 48-72 hours, smaller portion sizes, longer time between meals, reduced food cravings, mild nausea during titration, and steady weight loss of 0.5-2 pounds per week. You should also see improvements in fasting glucose, blood pressure, and energy levels.

Is there a genetic test to predict Zepbound response? Not yet in routine clinical practice. Research has identified GLP-1 receptor polymorphisms (rs6923761, rs10305492) that predict poor response, but commercial genetic testing for these variants is not widely available. Baseline metabolic markers (fasting insulin, HOMA-IR) are better practical predictors.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes. 2010.
5. Svendsen B et al. Insulin secretion depends on intra-islet glucagon signaling. Cell Reports. 2018.
6. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity. Lancet Diabetes & Endocrinology. 2023.
7. Kreutzer C et al. Hypothalamic inflammation in human obesity is mediated by environmental and genetic factors. Diabetes. 2017.
8. Dao MC et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity. Nature. 2016.
9. Mayfield K et al. Glucagon-like peptide-1 receptor agonists for weight management in antipsychotic-induced weight gain. Journal of Clinical Psychiatry. 2021.
10. Chirinos JA et al. CPAP, weight loss, or both for obstructive sleep apnea. New England Journal of Medicine. 2014.
11. Grilo CM et al. Binge eating disorder and weight loss outcomes. Obesity. 2020.
12. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue. Diabetes, Obesity and Metabolism. 2023.
13. Wilding JPH et al. Real-world effectiveness of GLP-1 receptor agonists. Obesity. 2023.
14. Davies MJ et al. Gastrointestinal adverse events with GLP-1 receptor agonists. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.